Korbel Gregory Alan 4
4 · Aprea Therapeutics, Inc. · Filed Dec 3, 2021
Insider Transaction Report
Form 4
Korbel Gregory Alan
VP of Business Dev't
Transactions
- Exercise/Conversion
Common Stock
2021-12-01$0.92/sh+27,500$25,300→ 44,667 total - Exercise/Conversion
Stock Option (right to Buy)
2021-12-01−27,500→ 2,335 totalExercise: $0.92Exp: 2027-02-16→ Common Stock (27,500 underlying) - Sale
Common Stock
2021-12-01$3.96/sh−27,500$108,900→ 17,167 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $4.12 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option was granted on February 26, 2017 and is fully exercisable.